Patents by Inventor Marc Cantillon

Marc Cantillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating pulmonary hypertension
    Patent number: 10441590
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 15, 2019
    Assignee: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Marc Cantillon, Ellen M. Wallis, Seema Rani Bhat
  • METHODS FOR TREATING PARKINSON'S DISEASE
    Publication number: 20190142838
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating Parkinson's disease. The method is particularly effective for treating cognitive impairment associated with Parkinson's disease. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula I, which is an arylpiperazine derivative.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 16, 2019
    Inventors: Laxminarayan BHAT, Marc Cantillon, Seema Rani Bhat
  • METHODS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20180125851
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: July 7, 2017
    Publication date: May 10, 2018
    Inventors: Laxminarayan Bhat, Marc Cantillon, Ellen M. Wallis, Seema Rani Bhat
  • METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE
    Publication number: 20180071299
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating psychosis associated with Parkinson's disease. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: July 7, 2017
    Publication date: March 15, 2018
    Inventors: Laxminarayan BHAT, Marc CANTILLON, Seema Rani BHAT
  • METHODS FOR TREATING ALZHEIMER'S DISEASE
    Publication number: 20180071298
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating behavioral and psychological symptoms in Alzheimer's disease patients. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: July 7, 2017
    Publication date: March 15, 2018
    Inventors: Laxminarayan BHAT, Marc Cantillon, Seema Rani Bhat
  • METHODS OF ALLEVIATING OR TREATING SIGNS AND/OR SYMPTOMS ASSOCIATED WITH MODERATE TO SEVERE PARKINSON'S DISEASE
    Publication number: 20120053182
    Abstract: The present invention provides a method for alleviating motor complications and motor indications in a patient suffering from moderate to severe Parkinson's disease by administering a composition which provides an effective amount of the compound of Formula I.
    Type: Application
    Filed: January 13, 2010
    Publication date: March 1, 2012
    Applicant: SCHERING CORPORATION
    Inventors: Marc Cantillon, Susan B. Huyck, Kenneth P. Wolski
  • Compositions and methods for treating or preventing memory impairment
    Publication number: 20040044023
    Abstract: The present invention relates to pharmaceutical compositions for treatment or prevention of memory impairment which comprise a cholinesterase inhibitor and at least one other pharmacologically active agent selected from HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, gamma or beta secretase inhibitors, NMDA antagonists, muscarinic receptor agonists and nicotinic receptor agonists. Additionally, the present invention relates to the use of these pharmaceutical compositions to treat or prevent memory impairment in a mammal, such as a human.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 4, 2004
    Inventor: Marc Cantillon